EGO-COMBO Angiographic Extension Study

NACompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
Coronary Disease
Interventions
DEVICE

The COMBO Stent

The COMBO Stent is developed basing on the GENOUS stent platform, and in addition, it also delivers a drug called sirolimus to the treated coronary blood vessel. The stent's original CD34 antibody coating is designed to promote healing of the coronary artery by catching circulating endothelial progenitor cells as they pass through the stent. These cells are naturally flowing in the circulation and are responsible for endothelial healing. This is intended to help the blood vessel wall heal over the stent more quickly and restore normal tissue function in the stented area. The combination of these two technologies in this new COMBO stent is expected to produce even better clinical results, which have been investigated in the previous REMEDEE Study.

Trial Locations (1)

Unknown

Department of Medicine, the University of Hong Kong, Queen Mary Hospital, Hospital Authority, Hong Kong

All Listed Sponsors
lead

Prof. Stephen Lee

OTHER

NCT01756807 - EGO-COMBO Angiographic Extension Study | Biotech Hunter | Biotech Hunter